Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
Top Page
Connect Biopharma Holdings
(NASDAQ:CNTB)
Select Model
Select Model
Rating:55Neutral
Price Target:
$2.50
▼(-11.35% Downside)
Action:ReiteratedDate:04/03/26
Overall score is held back primarily by weak financial performance (zero 2025 revenue, sizable ongoing losses, and heavy cash burn), partially offset by a constructive technical trend and positive corporate updates (encouraging clinical results and financing that extends operating runway). Valuation is neutral-to-weak due to unprofitability and no dividend support.
Positive Factors
Clinical Progress (Rademikibart)
Phase 1 data showing rapid, durable FEV1 gains and a favorable safety profile materially strengthens the drug's development thesis. Durable clinical efficacy and tolerability raise the probability of successful late-stage trials, partnering interest, and eventual commercialization, benefiting long-term program value.
Negative Factors
No Product Revenue
The company recorded zero product revenue in 2025, leaving it pre-commercial and without recurring sales. This structural lack of operating revenue makes the business dependent on financings or partnerships, increasing execution and funding risk if clinical timelines slip or approvals are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress (Rademikibart)
Phase 1 data showing rapid, durable FEV1 gains and a favorable safety profile materially strengthens the drug's development thesis. Durable clinical efficacy and tolerability raise the probability of successful late-stage trials, partnering interest, and eventual commercialization, benefiting long-term program value.
Read all positive factors
Connect Biopharma Holdings (CNTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$159.39M
Dividend YieldN/A
Average Volume (3M)97.97K
Price to Earnings (P/E)―
Beta (1Y)-0.17
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding56,521,282
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue1.90K
Enterprise Value/Gross Profit1.90K
Enterprise Value/Ebitda-4.26
Forecast
1Y Price Target
$8.38Price Target Upside197.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.26
Revenue Forecast (FY)$51.69M
Connect Biopharma Holdings Business Overview & Revenue Model
Company Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate i...
How the Company Makes Money
Connect Biopharma is a clinical-stage biotech and, based on publicly available descriptions of its stage of development, it has historically not had recurring product sales as a primary revenue source (null for material commercial revenue from mar...
Connect Biopharma Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.00K | 26.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 64.00K | 26.03M | 0.00 | 0.00 | 0.00 |
| EBITDA | -57.37M | -21.79M | -68.34M | -116.74M | -201.36M |
| Net Income | -55.48M | -15.63M | -62.11M | -118.09M | -202.27M |
Balance Sheet | |||||
| Total Assets | 56.08M | 101.28M | 127.38M | 174.01M | 291.05M |
| Cash, Cash Equivalents and Short-Term Investments | 44.34M | 93.71M | 118.30M | 152.42M | 267.72M |
| Total Debt | 690.00K | 178.00K | 465.00K | 431.00K | 125.00K |
| Total Liabilities | 14.10M | 9.12M | 25.88M | 16.52M | 18.80M |
| Stockholders Equity | 41.98M | 92.17M | 101.50M | 157.49M | 272.26M |
Cash Flow | |||||
| Free Cash Flow | -51.64M | -24.36M | -48.22M | -103.55M | -93.03M |
| Operating Cash Flow | -51.21M | -23.61M | -47.93M | -99.27M | -85.57M |
| Investing Cash Flow | 9.82M | -3.45M | 75.16M | -83.44M | -5.34M |
| Financing Cash Flow | 1.09M | 227.00K | -246.00K | -91.28K | 206.66M |
Connect Biopharma Holdings Technical Analysis
Positive
2.82
Price Trends
2.72
Positive
2.62
Positive
2.16
Positive
Market Momentum
0.02
Positive
49.71
Neutral
16.55
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTB, the sentiment is Positive. The current price of 2.82 is below the 20-day moving average (MA) of 2.91, above the 50-day MA of 2.72, and above the 200-day MA of 2.16, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.71 is Neutral, neither overbought nor oversold. The STOCH value of 16.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTB.
Connect Biopharma Holdings Risk Analysis
Connect Biopharma Holdings disclosed 121 risk factors in its most recent earnings report. Connect Biopharma Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The proposed revision of the EU legislation on pharmaceuticals could lead to uncertainties over the regulatory framework that will be applicable to medicinal products in the EU, including orphan medicinal products. Q4, 2023
2.
We are subject to risks arising from potential health epidemics. Q4, 2023
Connect Biopharma Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $159.39M | -2.83 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $2.01M | -0.20 | ― | ― | 178.82% | -4121.10% | |
44 Neutral | $4.91M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $11.64M | -0.15 | -356.99% | ― | ― | 54.62% | |
42 Neutral | $4.35M | -0.22 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
CNTB
Connect Biopharma Holdings
2.82
2.17
333.85%
SCNI
Scinai Immunotherapeutics
0.58
-1.42
-71.00%
GTBP
GT Biopharma
0.37
-1.92
-83.86%
REVB
Revelation Biosciences
1.17
-40.59
-97.20%
DRMA
Dermata Therapeutics
1.22
-6.87
-84.92%
CERO
CERo Therapeutics Holdings
0.03
-13.39
-99.78%
Connect Biopharma Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results
Positive
Mar 30, 2026
On March 29, 2026, Connect Biopharma entered into a securities purchase agreement for a $20.2 million private placement of 6,130,000 ordinary shares at $3.25 per share, with closing expected on March 31, 2026, to strengthen its balance sheet under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.